Hormonal
GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).
Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.
Tirzepatide is the first medical therapy approved for OSA by the Food and Drug Administration, with the SURMOUNT-OSA trial demonstrating improvements in the apnea-hypopnea index (AHI) at 52 weeks in those with obesity and moderate–severe OSA... The mean AHI improved by greater than half, with a reduction by 29.3 events/h... in those using positive airway pressure (PAP).
Why this rating
Based on RCTs (SURMOUNT-OSA, liraglutide trials), but long-term cardiovascular outcome data for OSA is pending.
Source
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Andrew-Hyun Lee et al. · Healthcare · 2026
DOI 10.3390/healthcare14060734
More from this paper
- GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.Strong
- GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.Strong
- GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →